Smoking and atherosclerosis: Mechanisms of disease and new therapeutic approaches

Current Medicinal Chemistry

Volumn 21, Issue 34, 2014, Pages 3936-3948

  Siasos, Gerasimos ^a   Tsigkou, Vasiliki ^a   Kokkou, Eleni ^a   Oikonomou, Evangelos ^a   Vavuranakis, Manolis ^a   Vlachopoulos, Charalambos ^a   Verveniotis, Alexis ^a   Limperi, Maria ^a   Genimata, Vasiliki ^a   Papavassiliou, Athanasios G ^a   Stefanadis, Christodoulos ^a   Tousoulis, Dimitris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Cardiovascular disease; Smoking

Indexed keywords

AMFEBUTAMONE; NICOTINE VACCINE; OPIATE ANTAGONIST; VARENICLINE;

ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY SPASM; DIET; EXERCISE; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; LIPID ANALYSIS; NICOTINE REPLACEMENT THERAPY; OXIDATIVE STRESS; PASSIVE SMOKING; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; SMOKING; SMOKING CESSATION; THROMBOSIS; TOBACCO DEPENDENCE; VASCULAR DISEASE;

EID: 84919603678     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986732134141015161539     Document Type: Article

References (201)

1. Hammond, D. Smoking behaviour among young adults: beyond youth prevention. Tob. Control., 2005, 14(3), 181-185.
2. Tobacco Control: Country profiles. Atlanta, GA: American Cancer Society; 2000.
3. Report On Tobacco Control In India. New Delhi: Ministry Of Health And Family Welfare, Govt. Of India; Centers For Disease Control And Prevention. USA: World Health Organization; 2004.
4. Trinidad, D. R.; Perez-Stable, E. J.; Emery, S. L.; White, M. M.; Grana, R. A.; Messer, K. S. Intermittent and light daily smoking across racial/ethnic groups in the United States. Nicotine Tob. Res., 2009, 11(2), 203-210.
5. Schane, R. E.; Glantz, S. A.; Ling, P. M. Nondaily and social smoking: an increasingly prevalent pattern. Arch. Intern. Med., 2009, 169(19), 1742-1744.
6. Prevalence of stroke-United States, 2005. MMWR Morb. Mortal. Wkly Rep., 2007, 56(19), 469-474.
7. Prevalence of heart disease-United States, 2005. MMWR Morb. Mortal Wkly Rep., 2007, 56(6), 113-118.
8. Campisi, R.; Czernin, J.; Schoder, H.; Sayre, J. W.; Marengo, F. D.; Phelps, M. E.; Schelbert, H. R. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation, 1998, 98(2), 119-125.
9. Barnoya, J.; Glantz, S. A. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation, 2005, 111(20), 2684-2698.
10. Glantz, S. A.; Parmley, W. W. Passive smoking and heart disease. Mechanisms and risk. JAMA, 1995, 273(13), 1047-1053.
11. Murray, C. J.; Lopez, A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997, 349(9061), 1269-1276.
12. Ockene, I. S.; Miller, N. H. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation, 1997, 96(9), 3243-3247.
13. He, J.; Ogden, L. G.; Bazzano, L. A.; Vupputuri, S.; Loria, C; Whelton, P. K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch. Intern. Med., 2001, 161(7), 996-1002.
14. Ambrose, J. A.; Barua, R. S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol., 2004, 43(10), 1731-1737.
15. Taioli, E. Gene-environment interaction in tobacco-related cancers. Carcinogenesis, 2008, 29(8), 1467-1474.
16. US Department of Health and Human Services. The health consequences of involuntary smoking. A Report of the Surgeon General. Rockville, MD: Public Health Service, Center For Disease Control. Center for Health Promotion and Education, Office on Smoking and Health. DHHS Publication, no. (CDC) 1981, 87-8398.
17. Koch, A.; Hoffmann, K.; Steck, W.; Horsch, A.; Hengen, N.; Morl, H.; Harenberg, J.; Spohr, U.; Weber, E. Acute cardiovascular reactions after cigarette smoking. Atherosclerosis, 1980, 35(1), 67-75.
18. Cryer, P. E.; Haymond, M. W.; Santiago, J. V.; Shah, S. D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med., 1976, 295(11), 573-577.
19. Ball, K.; Turner, R. Smoking and the heart. The basis for action. Lancet, 1974, 2(7884), 822-826.
20. Hagstad, S.; Bjerg, A.; Ekerljung, L.; Backman, H.; Lindberg, A.; Ronmark, E.; Lundback, B. Passive smoking exposure is associated with increased risk of COPD in never-smokers. Chest, 2014, 145(6), 1298-1304.
21. Prugger, C; Wellmann, J.; Heidrich, J.; De Bacquer, D.; Perier, M. C.; Empana, J. P.; Reiner, Z.; Fras, Z.; Jennings, C; Kotseva, K.; Wood, D.; Keil, U.; EUROASPIRE Study Group. Passive smoking and smoking cessation among patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur. Heart J., 2014, 35(9), 590-598.
22. Cohen, G.; Vardavas, C; Patelarou, E.; Kogevinas, M.; Katz-Salamon, M. Adverse circulatory effects of passive smoking during infancy: surprisingly strong, manifest early, easily avoided. Acta Paediatr., 2014, 103(4), 386-392.
23. Hughes, J. R. Tobacco withdrawal in self-quitters. J. Consult. Clin. Psychol, 1992, 60(5), 689-697.
24. Benowitz, N. L. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am. J. Med., 2008, 121(4 Suppl 1), S3-S10.
25. Leone A. Biochemistry of smoking compounds. In: Coronary circulation in nonsmokers and smokers. Leone A, Ed. New York: Nova Science Publishers, Inc. 2008, pp. 79-100.
26. Stratton, K.; Shetty, P.; Wallace, R.; Bondurant, S. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington, DC: Institute of Medicine, National Academy Press, 2001.
27. Wang, H.; Sun, X. Desensitized nicotinic receptors in brain. Brain Res. Brain Res. Rev., 2005, 48(3), 420-437.
28. Talhout, R.; Opperhuizen, A.; Van Amsterdam, J. G. Role of acetaldehyde in tobacco smoke addiction. Eur. Neuropsychopharmacol., 2007, 17(10), 627-636.
29. Yuan, H.; Wong, L. S.; Bhattacharya, M.; Ma, C; Zafarani, M.; Yao, M.; Schneider, M.; Pitas, R. E.; Martins-Green, M. The effects of second-hand smoke on biological processes important in atherogenesis. BMC Cardiovasc. Disord., 2007, 7, 1.
30. Siasos, G.; Tousoulis, D.; Siasou, Z.; Stefanadis, C.; Papavassiliou, A. G. Papavassiliou. Shear stress, protein kinases and atherosclerosis. Curr. Med. Chem., 2007, 14(14), 1567-1572.
31. Kampoli, A. M.; Tousoulis, D.; Antoniades, C.; Siasos, G.; Stefanadis, C. Biomarkers of premature atherosclerosis. Trends Mol. Med., 2009, 15(7), 323-332.
32. Yusuf, S.; Hawken, S.; Ounpuu, S.; Dans, T.; Avezum, A.; Lanas, F.; McQueen, M.; Budaj, A.; Pais, P.; Varigos, J.; Lisheng, L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004, 364(9438), 937-952.
33. Siasos, G.; Tousoulis, D.; Athanasiou, D.; Oikonomou, E.; Tourikis, P.; Gouliopoulos, N.; Limperi, M.; Kampoli, A. M.; Toutouzas, K.; Papavassiliou, A. G.; Stefanadis, C. Novel risk factors related to stable angina. Curr. Pharm. Des., 2013, 19(9), 1550-1561.
34. Flouris, A. D.; Vardavas, C. I.; Metsios, G. S.; Tsatsakis, A. M.; Koutedakis, Y. Biological evidence for the acute health effects of secondhand smoke exposure. Am. J. Physiol. Lung Cell Mol. Physiol., 2010, 298(1), L3-L12.
35. Harris, B.; Klein, R.; Jerosch-Herold, M.; Hoffman, E. A.; Ahmed, F. S.; Jacobs, D. R. Jr.; Klein, B. E.; Wong, T. Y.; Lima, J. A.; Cotch, M. F.; Barr, R. G. The association of systemic microvascular changes with lung function and lung density: a cross-sectional study. PLoS One, 2012, 7(12), e50224.
36. Carty, C. S.; Soloway, P. D.; Kayastha, S.; Bauer, J.; Marsan, B.; Ricotta, J. J.; Dryjski, M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J. Vasc. Surg., 1996, 24(6), 927-934; discussion 934-925.
37. Zhang, Q.; Tang, X.; Zhang, Z. F.; Velikina, R.; Shi, S.; Le, A. D. Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptormediated signaling pathways. Clin. Cancer Res., 2007, 13(16), 4686-4694.
38. Panagiotakos, D. B.; Pitsavos, C.; Chrysohoou, C.; Skoumas, J.; Masoura, C.; Toutouzas, P.; Stefanadis, C. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am. J. Med., 2004, 116(3), 145-150.
39. Chelland Campbell, S.; Moffatt, R. J.; Stamford, B. A. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis, 2008, 201(2), 225-235.
40. Armani, C.; Landini, L. Jr.; Leone, A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr. Pharm. Des., 2009, 15(10), 1038-1053.
41. Davi, G.; Di Minno, G.; Coppola, A.; Andria, G.; Cerbone, A. M.; Madonna, P.; Tufano, A.; Falco, A.; Marchesani, P.; Ciabattoni, G.; Patrono, C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation, 2001, 104(10), 1124-1128.
42. Durand, P.; Lussier-Cacan, S.; Blache, D. Acute methionine loadinduced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J., 1997, 11(13), 1157-1168.
43. Fusegawa, Y.; Goto, S.; Handa, S.; Kawada, T.; Ando, Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb. Res., 1999, 93(6), 271-278.
44. Barua, R. S.; Ambrose, J. A.; Saha, D. C.; Eales-Reynolds, L. J. Smoking is associated with altered endothelial-derived fibrinolytic and antithrombotic factors: an in vitro demonstration. Circulation, 2002, 106(8), 905-908.
45. Sambola, A.; Osende, J.; Hathcock, J.; Degen, M.; Nemerson, Y.; Fuster, V.; Crandall, J.; Badimon, J. J. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation, 2003, 107(7), 973-977.
46. Arkebauer, M. R.; Kanaparthy, S. S.; Malayaman, S. N.; Vosseller, K.; Nielsen, V. G. Carbon monoxide and nitric oxide modulate alpha (2)-antiplasmin and plasmin activity: role of heme. Blood Coagul. Fibrinolysis, 2011, 22(8), 712-719.
47. Chen, K. Y.; Rha, S. W.; Li, Y. J.; Jin, Z.; Minami, Y.; Park, J. Y.; Poddar, K. L.; Ramasamy, S.; Wang, L.; Li, G. P.; Choi, C. U.; Oh, D. J.; Jeong, M. H. ' Smoker's paradox' in young patients with acute myocardial infarction. Clin. Exp. Pharmacol. Physiol., 2012, 39(7), 630-635.
48. Tedgui, A. Mallat, Z. Anti-inflammatory mechanisms in the vascular wall. Circ. Res., 2001, 88(9), 877-887.
49. Bowie, A.; O'Neill, L. A. Oxidative stress and nuclear factorkappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem. Pharmacol., 2000, 59(1), 13-23.
50. Pelletier, C.; Varin-Blank, N.; Rivera, J.; Iannascoli, B.; Marchand, F.; David, B.; Weyer, A.; Blank, U. Fc epsilonRI-mediated induction of TNF-alpha gene expression in the RBL-2H3 mast cell line: regulation by a novel NF-kappaB-like nuclear binding complex. J. Immunol., 1998, 161(9), 4768-4776.
51. Collart, M. A.; Baeuerle, P.; Vassalli, P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell. Biol., 1990, 10(4), 1498-1506.
52. Csiszar, A.; Podlutsky, A.; Wolin, M. S.; Losonczy, G.; Pacher, P.; Ungvari, Z. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front. Biosci. (Landmark Ed.), 2009, 14, 3128-3144.
53. Bermudez, E. A.; Rifai, N.; Buring, J. E.; Manson, J. E.; Ridker, P. M. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol., 2002, 89(9), 1117-1119.
54. Mao, J.; Liu, J.; Pang, X.; Li, M.; Song, J.; Han, C.; Wu, D.; Wang, S. Nicotine induces the expression of C-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Mol. Cells, 2012, 34(5), 457-461.
55. Arunachalam, G.; Yao, H.; Sundar, I. K.; Caito, S.; Rahman, I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem. Biophys. Res. Commun., 2010, 393(1), 66-72.
56. Edirisinghe, I.; Rahman, I. Cigarette smoke-mediated oxidative stress, shear stress, and endothelial dysfunction: role of VEGFR2. Ann. N. Y. Acad. Sci., 2010, 1203, 66-72.
57. Rahman, M. M.; Elmi, S.; Chang, T. K.; Bai, N.; Sallam, N. A.; Lemos, V. S.; Moien-Afshari, F.; Laher, I. Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release. Vascul. Pharmacol., 2007, 46(1), 35-42.
58. Jaimes, E. A.; De Master, E. G.; Tian, R. X.; Raij, L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler. Thromb. Vasc. Biol., 2004, 24(6), 1031-1036.
59. Orosz, Z.; Csiszar, A.; Labinskyy, N.; Smith, K.; Kaminski, P. M.; Ferdinandy, P.; Wolin, M. S.; Rivera, A.; Ungvari, Z. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role of NAD (P) H oxidase activation. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(1), H130-139.
60. Mur, C.; Claria, JK.; Rodela, S.; Lario, S.; Campistol, J. M.; Titos, E.; Inigo, P.; Cases, A.; Abian, J.; Esmatjes, E. Cigarette smoke concentrate increases 8-epi-PGF2alpha and TGFbeta1 secretion in rat mesangial cells. Life Sci., 2004, 75(5), 611-621.
61. Reddy, S.; Finkelstein, E. I.; Wong, P. S.; Phung, A.; Cross, C. E.; Van Der Vliet, A. Identification of glutathione modifications by cigarette smoke. Free Radic. Biol. Med., 2002, 33(11), 1490-1498.
62. Lancel, S.; Tissier, S.; Mordon, S.; Marechal, X.; Depontieu, F.; Scherpereel, A.; Chopin, C.; Neviere, R. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J. Am. Coll. Cardiol., 2004, 43(12), 2348-2358.
63. Pacher, P.; Schulz, R.; Liaudet, L.; Szabo, C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol. Sci., 2005, 26(6), 302-310.
64. Pacher, P.; Beckman, J. S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87(1), 315-424.
65. Yamaguchi, Y.; Nasu, F.; Harada, A.; Kunitomo, M. Oxidants in the gas phase of cigarette smoke pass through the lung alveolar wall and raise systemic oxidative stress. J. Pharmacol. Sci., 2007, 103(3), 275-282.
66. Jozsef, L.; Khreiss, T.; El Kebir, D.; Filep, J. G. Activation of TLR-9 induces IL-8 secretion through peroxynitrite signaling in human neutrophils. J. Immunol., 2006, 176(2), 1195-1202.
67. Sztalryd, C.; Hamilton, J.; Horwitz, B. A.; Johnson, P.; Kraemer, F. B. Alterations of lipolysis and lipoprotein lipase in chronically nicotine-treated rats. Am. J. Physiol., 1996, 270(2 Pt 1), E215-223.
68. Valkonen, M.; Kuusi, T. Passive smoking induces atherogenic changes in low-density lipoprotein. Circulation, 1998, 97(20), 2012-2016.
69. Milionis, H. J.; Elisaf, M. S.; Mikhailidis, D. P. The effects of lipidregulating therapy on haemostatic parameters. Curr. Pharm. Des., 2003, 9(29), 2425-2443.
70. Eliasson, B. Cigarette smoking and diabetes. Prog Cardiovasc Dis, 2003, 45(5), 405-413.
71. Chiolero, A.; Faeh, D.; Paccaud, F.; Cornuz, J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am. J. Clin. Nutr., 2008, 87(4), 801-809.
72. Antoniades, C.; Tousoulis, D.; Stefanadis, C. Smoking in Asians: it doesn't stop at vascular endothelium. Int. J. Cardiol., 2008, 128(2), 151-153.
73. Yokoyama, M. Oxidant stress and atherosclerosis. Curr. Opin. Pharmacol., 2004, 4(2), 110-115.
74. Leone, A. Interactive effect of combined exposure to active and passive smoking on cardiovascular system. Recent Pat. Cardiovasc. Drug Discov., 2011, 6(1), 61-69.
75. Milara, J.; Ortiz, J. L.; Juan, G.; Guijarro, R.; Almudever, P.; Martorell, M.; Morcillo, E. J.; Cortijo, J. Cigarette smoke exposure upregulates endothelin receptor B in human pulmonary artery endothelial cells: molecular and functional consequences. Br. J. Pharmacol., 2010, 161(7), 1599-1615.
76. Vayssettes-Courchay, C.; Ragonnet, C.; Camenen, G.; Feletou, M.; Cordi, A. A.; Lavielle, G.; Verbeuren, T. J. Role of thromboxane TP and angiotensin AT1 receptors in lipopolysaccharide-induced arterial dysfunction in the rabbit: an in vivo study. Eur. J. Pharmacol., 2010, 634(1-3), 113-120.
77. Tada, M.; Kuzuya, T.; Inoue, M.; Kodama, K.; Mishima, M.; Yamada, M.; Inui, M.; Abe, H. Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris. Circulation, 1981, 64(6), 1107-1115.
78. Forstermann, U.; Munzel, T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation, 2006, 113(13), 1708-1714.
79. Puranik, R.; Celermajer, D. S. Smoking and endothelial function. Prog. Cardiovasc. Dis., 2003, 45(6), 443-458.
80. Griendling, K. K.; Fitz Gerald, G. A. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation, 2003, 108(16), 1912-1916.
81. Blake, G. J.; Ridker, P. M. Novel clinical markers of vascular wall inflammation. Circ. Res., 2001, 89(9), 763-771.
82. Gu, Z.; Fonseca, V.; Hai, C. M. Nicotinic acetylcholine receptor mediates nicotine-induced actin cytoskeletal remodeling and extracellular matrix degradation by vascular smooth muscle cells. Vascul. Pharmacol., 2013, 58(1-2), 87-97.
83. Ng, M. K.; Wu, J.; Chang, E.; Wang, B. Y.; Katzenberg-Clark, R.; Ishii-Watabe, A.; Cooke, J. P. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler. Thromb. Vasc. Biol., 2007, 27(1), 106-112.
84. Tsai, J. S.; Guo, F. R.; Chen, S. C.; Lue, B. H.; Chiu, T. Y.; Chen, C. Y.; Hung, S. H.; Chuang, L. M.; Chen, C. Y. Smokers show reduced circulating adiponectin levels and adiponectin mRNA expression in peripheral blood mononuclear cells. Atherosclerosis, 2011, 218(1), 168-173.
85. Siasos, G.; Tousoulis, D.; Kollia, C.; Oikonomou, E.; Siasou, Z.; Stefanadis, C.; Papavassiliou, A. G. Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Curr. Med. Chem., 2012, 19(8), 1193-1209.
86. Haj Mouhamed, D.; Ezzaher, A.; Neffati, F.; Douki, W.; Najjar, M. F. Effect of cigarette smoking on plasma homocysteine concentrations. Clin. Chem. Lab. Med., 2011, 49(3), 479-483.
87. Antoniades, C.; Tousoulis, D.; Vasiliadou, C.; Marinou, K.; Tentolouris, C.; Ntarladimas, I.; Stefanadis, C. Combined effects of smoking and hypercholesterolemia on inflammatory process, thrombosis/fibrinolysis system, and forearm hyperemic response. Am. J. Cardiol., 2004, 94(9), 1181-1184.
88. Ichiki, K.; Ikeda, H.; Haramaki, N.; Ueno, T.; Imaizumi, T. Longterm smoking impairs platelet-derived nitric oxide release. Circulation, 1996, 94(12), 3109-3114.
89. Newby, D. E.; McLeod, A. L.; Uren, N. G.; Flint, L.; Ludlam, C. A.; Webb, D. J.; Fox, K. A.; Boon, N. A. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation, 2001, 103(15), 1936-1941.
90. Miyaura, S.; Eguchi, H.; Johnston, J. M. Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ. Res., 1992, 70(2), 341-347.
91. Lupia, E.; Bosco, O.; Goffi, A.; Poletto, C.; Locatelli, S.; Spatola, T.; Cuccurullo, A.; Montrucchio, G. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis, 2010, 210(1), 314-319.
92. Caponnetto, P.; Russo, C.; Di Maria, A.; Morjaria, J. B.; Barton, S.; Guarino, F.; Basile, E.; Proiti, M.; Bertino, G.; Cacciola, R. R.; Polosa, R. Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur. J. Clin. Invest., 2011, 41(6), 616-626.
93. Ross, R. Atherosclerosis is an inflammatory disease. Am. Heart J., 1999, 138(5 Pt 2), S419-420.
94. Pryor, W. A.; Stone, K.; Zang, L. Y.; Bermudez, E. Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem. Res. Toxicol., 1998, 11(5), 441-448.
95. Zang, L. Y.; Stone, K.; Pryor, W. A. Detection of free radicals in aqueous extracts of cigarette tar by electron spin resonance. Free Radic. Biol. Med., 1995, 19(2), 161-167.
96. Csiszar, A.; Ungvari, Z.; Koller, A.; Edwards, J. G.; Kaley, G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J., 2003, 17(9), 1183-1185.
97. Csiszar, A.; Ungvari, Z.; Koller, A.; Edwards, J. G.; Kaley, G. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. Physiol. Genomics, 2004, 17(1), 21-30.
98. Siasos, G.; Kollia, C.; Tsigkou, V.; Basdra, E. K.; Lymperi, M.; Oikonomou, E.; Kokkou, E.; Korompelis, P.; Papavassiliou, A. G. MicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis. Curr. Top. Med. Chem., 2013, 13(13), 1503-1517.
99. Nordskog, B. K.; Blixt, A. D.; Morgan, W. T.; Fields, W. R.; Hellmann, G. M. Matrix-degrading and pro-inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate. Cardiovasc. Toxicol., 2003, 3(2), 101-117.
100. Yang, S. R.; Wright, J.; Bauter, M.; Seweryniak, K.; Kode, A.; Rahman, I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 292(2), L567-576.
101. Csiszar, A.; Smith, K.; Labinskyy, N.; Orosz, Z.; Rivera, A.; Ungvari, Z. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(4), H1694-1699.
102. Hassa, P. O.; Covic, M.; Hasan, S.; Imhof, R.; Hottiger, M. O. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J. Biol. Chem., 2001, 276(49), 45588-45597.
103. Xu, S.; Bai, P.; Little, P. J.; Liu, P. Poly (ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med. Res. Rev., 2014, 34(3), 644-675.
104. Jefferis, B. J.; Papacosta, O.; Owen, C. G.; Wannamethee, S. G.; Humphries, S. E.; Woodward, M.; Lennon, L. T.; Thomson, A.; Welsh, P.; Rumley, A.; Lowe, G. D.; Whincup, P. H. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis, 2011, 217(1), 227-233.
105. De Chiara, B.; Sedda, V.; Parolini, M.; Campolo, J.; De Maria, R.; Caruso, R.; Pizzi, G.; Disoteo, O.; Dellanoce, C.; Corno, A. R.; Cighetti, G.; Parodi, O. Plasma total cysteine and cardiovascular risk burden: action and interaction. ScientificWorldJournal, 2012, 2012, 303654.
106. Andersson, K.; Arner, P. Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int. J. Obes. Relat. Metab. Disord., 2001, 25(8), 1225-1232.
107. Hellerstein, M. K.; Benowitz, N. L.; Neese, R. A.; Schwartz, J. M.; Hoh, R.; Jacob, P., 3rd.; Hsieh, J.; Faix, D. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J. Clin. Invest., 1994, 93(1), 265-272.
108. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, 106(25), 3143-3421.
109. Kralova Lesna, I.; Poledne, R.; Pagacova, L.; Stavek, P. J. Pitha. HDL and apolipoprotein A1 concentrations as markers of cholesterol efflux in middle-aged women: interaction with smoking. Neuro. Endocrinol. Lett., 2012, 33 Suppl. 2, 38-42.
110. Bisanovic, S.; Mehic, B.; Sivic, S. Status of lipids and the frequency diseases of cardiovascular origin in smokers according to the length period of smoking and a number of cigarettes smoked daily. Bosn. J. Basic. Med. Sci., 2011, 11(1), 46-51.
111. Siasos, G.; Tousoulis, D.; Oikonomou, E.; Zaromitidou, M.; Stefanadis, C.; Papavassiliou, A. G. Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. Curr. Pharm. Des., 2011, 17(37), 4132-4146.
112. Zhou, M. S.; Chadipiralla, K.; Mendez, A. J.; Jaimes, E. A.; Silverstein, R. L.; Webster, K.; Raij, L. Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling. Am. J. Physiol. Heart Circ. Physiol., 2013, 305(4), H563-574.
113. Martinet, W.; Knaapen, M. W.; De Meyer, G. R.; Herman, A. G.; Kockx, M. M. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ. Res., 2001, 88(7), 733-739.
114. Yang, G.; Lucas, R.; Caldwell, R.; Yao, L.; Romero, M. J.; Caldwell, R. W. Novel mechanisms of endothelial dysfunction in diabetes. J. Cardiovasc. Dis. Res., 2010, 1(2), 59-63.
115. Tousoulis, D.; Siasos, G.; Oikonomou, E.; Stougianos, P.; Papageorgiou, N.; Papavassiliou, A. G.; Stefanadis, C. Asymmetric dimethylarginine (ADMA): is really a biomarker for cardiovascular prognosis? Int. J. Cardiol., 2011, 153(2), 123-125.
116. Zou, M. H.; Shi, C.; Cohen, R. A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest., 2002, 109(6), 817-826.
117. Tousoulis, D.; Boger, R. H.; Antoniades, C.; Siasos, G.; Stefanadi, E.; Stefanadis, C. Mechanisms of disease: L-arginine in coronary atherosclerosis-a clinical perspective. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4(5), 274-283.
118. Barbieri, S. S.; Zacchi, E.; Amadio, P.; Gianellini, S.; Mussoni, L.; Weksler, B. B.; Tremoli, E. Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc. Res., 2011, 90(3), 475-483.
119. Yanbaeva, D. G.; Dentener, M. A.; Creutzberg, E. C.; Wesseling, G.; Wouters, E. F. Systemic effects of smoking. Chest, 2007, 131(5), 1557-1566.
120. Gaenzer, H.; Neumayr, G.; Marschang, P.; Sturm, W.; Kirchmair, R.; Patsch, J. R. Flow-mediated vasodilation of the femoral and brachial artery induced by exercise in healthy nonsmoking and smoking men. J. Am. Coll. Cardiol., 2001, 38(5), 1313-1319.
121. Yugar-Toledo, J. C.; Tanus-Santos, J. E.; Sabha, M.; Sousa, M. G.; Cittadino, M.; Tacito, L. H.; Moreno, H. Jr. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest, 2004, 125(3), 823-830.
122. Vlachopoulos, C.; Tsekoura, D.; Alexopoulos, N.; Panagiotakos, D.; Aznaouridis, K.; Stefanadis, C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am. J. Hypertens., 2004, 17(11 Pt 1), 1040-1044.
123. Tousoulis, D.; Koutsogiannis, M.; Papageorgiou, N.; Siasos, G.; Antoniades, C.; Tsiamis, E.; Stefanadis, C. Endothelial dysfunction: potential clinical implications. Minerva Med., 2010, 101(4), 271-284.
124. Kallio, K.; Jokinen, E.; Raitakari, O. T.; Hamalainen, M.; Siltala, M.; Volanen, I.; Kaitosaari, T.; Viikari, J.; Ronnemaa, T.; Simell, O. Tobacco smoke exposure is associated with attenuated endothelial function in 11-year-old healthy children. Circulation, 2007, 115(25), 3205-3212.
125. Yang, B.; Li, M.; Chen, B.; Xu, Y.; Li, T. D. Deterioration of endothelial function and carotid intima-media thickness in Tibetan male adolescents exposed to second-hand smoke. J. Renin. Angiotensin. Aldosterone Syst., 2012, 13(4), 413-419.
126. Kubozono, T.; Miyata, M.; Ueyama, K.; Hamasaki, S.; Kusano, K.; Kubozono, O.; Tei, C. Acute and chronic effects of smoking on arterial stiffness. Circ. J., 2011, 75(3), 698-702.
127. Zatu, M. C.; Van Rooyen, J. M.; Schutte, A. E. Smoking and vascular dysfunction in Africans and Caucasians from South Africa. Cardiovasc. J. Afr., 2011, 22(1), 18-24.
128. Sanna, T.; Lanza, G. A.; Niccoli, G.; La Torre, G.; Cosentino, N.; Crea, F. Coronary artery vasospasm causing ventricular fibrillation - an external loop recording. Resuscitation, 2009, 80(4), 393-394.
129. Romagnoli, E.; Lanza, G. A. Acute myocardial infarction with normal coronary arteries: role of coronary artery spasm and arrhythmic complications. Int. J. Cardiol., 2007, 117(1), 3-5.
130. Sugiishi, M.; Takatsu, F. Cigarette smoking is a major risk factor for coronary spasm. Circulation, 1993, 87(1), 76-79.
131. Saitoh, T.; Kishida, H.; Hanashi, A.; Tsukada, Y.; Fukuma, Y.; Sano, J.; Fukuma, N.; Kusama, Y.; Hayakawa, H. Coronary hyperreactivity to adrenergic stimulation and increased nocturnal vagal tone trigger coronary vasospasm. Jpn. Circ. J., 1998, 62(10), 721-726.
132. Egashira, K.; Inou, T.; Yamada, A.; Hirooka, Y.; Takeshita, A. Preserved endothelium-dependent vasodilation at the vasospastic site in patients with variant angina. J. Clin. Invest., 1992, 89(3), 1047-1052.
133. Tentolouris, C.; Tousoulis, D.; Davies, G.; Tsioufis, C.; Kallikazaros, I.; Michailidis, A.; Trikas, A.; Toutouzas, P.; Stefanadis, C. Effects of smoking on nitric oxide synthesis in epicardial normal and atheromatous coronary arteries. Int. J. Cardiol., 2004, 95(1), 69-73.
134. Hirano, K. Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J. Pharmacol. Sci., 2007, 104(2), 109-115.
135. Park, K.; Gross, M.; Lee, D. H.; Holvoet, P.; Himes, J. H.; Shikany, J. M.; Jacobs, D. R. Jr. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care, 2009, 32(7), 1302-1307.
136. Rodrigo, R.; Gonzalez, J.; Paoletto, F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens. Res., 2011, 34(4), 431-440.
137. Kaneda, H.; Taguchi, J.; Kuwada, Y.; Hangaishi, M.; Aizawa, T.; Yamakado, M.; Ogasawara, K.; Ohno, M. Coronary artery spasm and the polymorphisms of the endothelial nitric oxide synthase gene. Circ. J., 2006, 70(4), 409-413.
138. Park, J. S.; Zhang, S. Y.; Jo, S. H.; Seo, J. B.; Li, L.; Park, K. W.; Oh, B. H.; Park, Y. B.; Kim, H. S. Common adrenergic receptor polymorphisms as novel risk factors for vasospastic angina. Am. Heart J., 2006, 151(4), 864-869.
139. Kaumann, A. J.; Levy, F. O. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther., 2006, 111(3), 674-706.
140. Yanagawa, N.; Tamura, G.; Oizumi, H.; Endoh, M.; Sadahiro, M.; Motoyama, T. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res., 2011, 31(4), 1211-1214.
141. Wang, X. L.; Mahaney, M. C.; Sim, A. S.; Wang, J.; Blangero, J.; Almasy, L.; Badenhop, R. B.; Wilcken, D. E. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler. Thromb. Vasc. Biol., 1997, 17(11), 3147-3153.
142. Wang, J.; Dudley, D.; Wang, X. L. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler. Thromb. Vasc. Biol., 2002, 22(5), e1-4.
143. Wang, X. L.; Greco, M.; Sim, A. S.; Duarte, N.; Wang, J.; Wilcken, D. E. Glutathione S-transferase mu1 deficiency, cigarette smoking and coronary artery disease. J. Cardiovasc. Risk, 2002, 9(1), 25-31.
144. Jia, E. Z.; Xu, Z. X.; Guo, C. Y.; Li, L.; Gu, Y.; Zhu, T. B.; Wang, L. S.; Cao, K. J.; Ma, W. Z.; Yang, Z. J. Renin-angiotensinaldosterone system gene polymorphisms and coronary artery disease: detection of gene-gene and gene-environment interactions. Cell. Physiol. Biochem., 2012, 29(3-4), 443-452.
145. U. S. Department of Health and Human Services. The health benefits of smoking cessation: a report of the surgeon general. Rockville, MD: U. S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, 1990.
146. Sean C Sweetman, editor. Martin dale. The complete drug reference. 33 ed. UK: Pharmaceutical press; 2002.
147. Caponnetto, P.; Cibella, F.; Mancuso, S.; Campagna, D.; Arcidiacono, G.; Polosa, R. Effect of a nicotine-free inhalator as part of a smoking-cessation programme. Eur. Respir. J., 2011, 38(5), 1005-1011.
148. Hays, J. T.; Ebbert, J. O. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin. Proc., 2003, 78(8), 1020-1024; quiz 1024.
149. Gonzales, D.; Rennard, S. I.; Nides, M.; Oncken, C.; Azoulay, S.; Billing, C. B.; Watsky, E. J.; Gong, J.; Williams, K. E.; Reeves, K. R. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 2006, 296(1), 47-55.
150. Cinciripini, P. M.; Robinson, J. D.; Karam-Hage, M.; Minnix, J. A.; Lam, C.; Versace, F.; Brown, V. L.; Engelmann, J. M.; Wetter, D. W. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry, 2013, 70(5), 522-533.
151. Brose, L. S.; West, R.; Stapleton, J. A. Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice. Mayo Clin. Proc., 2013, 88(3), 226-233.
152. King, A. C.; Cao, D.; O'Malley, S. S.; Kranzler, H. R.; Cai, X.; De Wit, H.; Matthews, A. K.; Stachoviak, R. J. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotinedependent men and women. J. Clin. Psychopharmacol., 2012, 32(5), 630-636.
153. Tonstad, S.; Holme, I.; Tonnesen, P. Dianicline, a novel alpha4beta2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine Tob. Res., 2011, 13(1), 1-6.
154. West, R.; Zatonski, W.; Cedzynska, M.; Lewandowska, D.; Pazik, J.; Aveyard, P.; Stapleton, J. Placebo-controlled trial of cytisine for smoking cessation. N. Engl. J. Med., 2011, 365(13), 1193-1200.
155. Kim, Y. J.; Jeong, D. W.; Lee, J. G.; Lee, H. C.; Lee, S. Y.; Yi, Y. H.; Park, Y. S.; Cho, Y. H.; Bae, M. J.; Choi, E. J. Omega-3 index and smoking in patients with acute ST-elevation myocardial infarction taking statins: a case-control study in Korea. Lipids Health Dis., 2012, 11, 43.
156. Din, J. N.; Archer, R. M.; Harding, S. A.; Sarma, J.; Lyall, K.; Flapan, A. D.; Newby, D. E. Effect of omega-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers. Heart, 2013, 99(3), 168-174.
157. Harris, W. S.; Pottala, J. V.; Lacey, S. M.; Vasan, R. S.; Larson, M. G.; Robins, S. J. Clinical correlates and heritability of erythrocyte eicosapentaenoic and docosahexaenoic acid content in the Framingham Heart Study. Atherosclerosis, 2012, 225(2), 425-431.
158. Guthikonda, S.; Sinkey, C.; Barenz, T.; Haynes, W. G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation, 2003, 107(3), 416-421.
159. Beckman, J. A.; Liao, J. K.; Hurley, S.; Garrett, L. A.; Chui, D.; Mitra, D.; Creager, M. A. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in lowdensity lipoprotein. Circ. Res., 2004, 95(2), 217-223.
160. Barua, R. S.; Ambrose, J. A.; Eales-Reynolds, L. J.; De Voe, M. C.; Zervas, J. G.; Saha, D. C. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation, 2001, 104(16), 1905-1910.
161. Adams, M. R.; Jessup, W.; Celermajer, D. S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J. Am. Coll. Cardiol., 1997, 29(3), 491-497.
162. De Villiers, S. H.; Lindblom, N.; Kalayanov, G.; Gordon, S.; Malmerfelt, A.; Johansson, A. M.; Svensson, T. H. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration, 2002, 69(3), 247-253.
163. Fahim, R. E.; Kesslerm, P. D.; Fuller, S. A.; Kalnik, M. W. Nicotine vaccines. CNS Neurol. Disord. Drug Targets, 2011, 10(8), 905-915.
164. ∗-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am. J. Psychiatry, 2013, 170(4), 399-407.
165. Serra-Majem, L.; De La Cruz, J. N.; Ribas, L.; Salleras, L. Mediterranean diet and health: is all the secret in olive oil? Pathophysiol. Haemost. Thromb., 2003, 33(5-6), 461-465.
166. Kafatos, A.; Verhagen, H.; Moschandreas, J.; Apostolaki, I.; Van Westerop, J. J. Mediterranean diet of Crete: foods and nutrient content. J. Am. Diet. Assoc., 2000, 100(12), 1487-1493.
167. Ferro-Luzzi, A.; James, W. P.; Kafatos, A. The high-fat Greek diet: a recipe for all? Eur. J. Clin. Nutr., 2002, 56(9), 796-809.
168. Riediger, N. D.; Othman, R. A.; Suh, M.; Moghadasian, M. H. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc., 2009, 109(4), 668-679.
169. Colussi, G.; Catena, C.; Baroselli, S.; Nadalini, E.; Lapenna, R.; Chiuch, A.; Sechi, L. A. Omega-3 fatty acids: from biochemistry to their clinical use in the prevention of cardiovascular disease. Recent Pat. Cardiovasc. Drug Discov., 2007, 2(1), 13-21.
170. Naidu, K. A. Vitamin C in human health and disease is still a mystery? An overview. Nutr. J., 2003, 2, 7.
171. Dwyer, J. H.; Navab, M.; Dwyer, K. M.; Hassan, K.; Sun, P.; Shircore, A.; Hama-Levy, S.; Hough, G.; Wang, X.; Drake, T.; Merz, C. N.; Fogelman, A. M. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation, 2001, 103(24), 2922-2927.
172. Loffredo, L.; Carnevale, R.; Perri, L.; Catasca, E.; Augelletti, T.; Cangemi, R.; Albanese, F.; Piccheri, C.; Nocella, C.; Pignatelli, P.; Violi, F. NOX2-mediated arterial dysfunction in smokers: acute effect of dark chocolate. Heart, 2011, 97(21), 1776-1781.
173. Wang, M. Y.; Peng, L.; Weidenbacher-Hoper, V.; Deng, S.; Anderson, G.; West, B. J. Noni juice improves serum lipid profiles and other risk markers in cigarette smokers. ScientificWorldJournal, 2012, 2012, 594657.
174. Bloomer, R. J.; Fisher-Wellman, K. The role of exercise in minimizing postprandial oxidative stress in cigarette smokers. Nicotine Tob. Res., 2009, 11(1), 3-11.
175. Smits, J. A.; Zvolensky, M. J.; Rosenfield, D.; Marcus, B. H.; Church, T. S.; Frierson; Powers, M. B.; Otto, M. W.; Davis, M. L.; De Boer, L. B.; Briceno, N. F. The efficacy of vigorous-intensity exercise as an aid to smoking cessation in adults with elevated anxiety sensitivity: study protocol for a randomized controlled trial. Trials, 2012, 13, 207.
176. Katano, H.; Ohno, M.; Yamada, K. Protection by physical activity against deleterious effect of smoking on carotid intima-media thickness in young Japanese. J. Stroke Cerebrovasc. Dis., 2013, 22(2), 176-183.
177. MacFarlane, K.; Paynter, J.; Arroll, B.; Youdan, B. Tax as a motivating factor to make a quit attempt from smoking: a study before and after the April 2010 tax increase. J. Prim. Health Care, 2011, 3(4), 283-288.
178. Menzies, D. The case for a worldwide ban on smoking in public places. Curr. Opin. Pulm. Med., 2011, 17(2), 116-122.
179. Katz, D. A.; Muehlenbruch, D. R.; Brown, R. L.; Fiore, M. C.; Baker, T. B. Effectiveness of implementing the agency for healthcare research and quality smoking cessation clinical practice guideline: a randomized, controlled trial. J. Natl. Cancer Inst., 2004, 96(8), 594-603.
180. Husten, C. G. L. R. Deyton. Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future. Lancet, 2013, 381(9877), 1570-1580.
181. Vlachopoulos, C.; Alexopoulos, N.; Panagiotakos, D.; O'Rourke, M. F.; Stefanadis, C. Cigar smoking has an acute detrimental effect on arterial stiffness. Am. J. Hypertens., 2004, 17(4), 299-303.
182. Henningfield, J. E. Nicotine medications for smoking cessation. N. Engl. J. Med., 1995, 333(18), 1196-1203.
183. Siegel, M. B.; Tanwar, K. L.; Wood, K. S. Electronic cigarettes as a smoking-cessation: tool results from an online survey. Am. J. Prev. Med., 2011, 40(4), 472-475.
184. Ferguson, S. G.; Gitchell, J. G.; Shiffman, S. Continuing to wear nicotine patches after smoking lapses promotes recovery of abstinence. Addiction, 2012, 107(7), 1349-1353.
185. Sun, H.; Guo, S.; Chen, D.; Yang, F.; Zou, Y.; Di, X.; Cao, Y.; Kosten, T.; Lu, L.; Zhang, X. Y. Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. J. Neural. Transm., 2012, 119(12), 1491-1498.
186. Hall, S. M.; Reus, V. I.; Munoz, R. F.; Sees, K. L.; Humfleet, G.; Hartz, D. T.; Frederick, S.; Triffleman, E. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry, 1998, 55(8), 683-690.
187. Quaak, M.; Van Schayck, C. P.; Postma, D. S.; Wagena, E. J.; Van Schooten, F. J. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction, 2012, 107(1), 178-187.
188. Siasos, G.; Tousoulis, D.; Kokkou, E.; Oikonomou, E.; Kollia, M. E.; Verveniotis, A.; Gouliopoulos, N.; Zisimos, K.; Plastiras, A.; Maniatis, K.; Stefanadis, C. Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers. Am. J. Hypertens., 2014, 27(1), 38-45.
189. Siasos, G.; Tousoulis, D.; Tsigkou, V.; Kokkou, E.; Oikonomou, E.; Vavuranakis, M.; Basdra, E. K.; Papavassiliou, A. G.; Stefanadis, C. Flavonoids in atherosclerosis: an overview of their mechanisms of action. Curr. Med. Chem., 2013, 20(21), 2641-2660.
190. Papageorgiou, N.; Tousoulis, D.; Katsargyris, A.; Charakida, M.; Androulakis, E.; Siasos, G.; Tentolouris, C.; Stefanadis, C. Antioxidant treatment and endothelial dysfunction: is it time for flavonoids? Recent Pat. Cardiovasc. Drug Discov., 2013, 8(2), 81-92.
191. Chrysohoou, C.; Skoumas, J.; Pitsavos, C.; Masoura, C.; Siasos, G.; Galiatsatos, N.; Psaltopoulou, T.; Mylonakis, C.; Margazas, A.; Kyvelou, S.; Mamatas, S.; Panagiotakos, D.; Stefanadis, C. Longterm adherence to the Mediterranean diet reduces the prevalence of hyperuricaemia in elderly individuals, without known cardiovascular disease: the Ikaria study. Maturitas, 2011, 70(1), 58-64.
192. Tousoulis, D.; Antoniades, C.; Tentolouris, C.; Tsioufis, C.; Toutouza, M.; Toutouzas, P.; Stefanadis, C. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis, 2003, 170(2), 261-267.
193. Siasos, G.; Tousoulis, D.; Oikonomou, E.; Zaromitidou, M.; Verveniotis, A.; Plastiras, A.; Kioufis, S.; Maniatis, K.; Miliou, A.; Siasou, Z.; Stefanadis, C.; Papavassiliou, A. G. Effects of omega-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int. J. Cardiol., 2013, 166(2), 340-346.
194. Das, A.; Dey, N.; Ghosh, A.; Das, S.; Chattopadhyay, D. J.; Chatterjee, I. B. Molecular and cellular mechanisms of cigarette smokeinduced myocardial injury: prevention by vitamin C. PLoS One, 2012, 7(9), e44151.
195. Siasos, G.; Chrysohoou, C.; Tousoulis, D.; Oikonomou, E.; Panagiotakos, D.; Zaromitidou, M.; Zisimos, K.; Marinos, G.; Mazaris, S.; Kampaksis, M.; Papavassiliou, A. G.; Pitsavos, C.; Stefanadis, C. The impact of physical activity on endothelial function in middle-aged and elderly subjects: the Ikaria study. Hellenic J. Cardiol., 2013, 54(2), 94-101.
196. Siasos, G.; Tousoulis, D.; Vlachopoulos, C.; Antoniades, C.; Stefanadi, E.; Ioakeimidis, N.; Zisimos, K.; Siasou, Z.; Papavassiliou, A. G.; Stefanadis, C. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. Am. J. Hypertens., 2009, 22(6), 586-592.
197. Siasos, G.; Tousoulis, D.; Vlachopoulos, C.; Antoniades, C.; Stefanadi, E.; Ioakeimidis, N.; Andreou, I.; Zisimos, K.; Papavassiliou, A. G.; Stefanadis, C. Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. Int. J. Cardiol., 2008, 126(3), 394-399.
198. Tousoulis, D.; Antoniades, C.; Tentolouris, C.; Goumas, G.; Stefanadis, C.; Toutouzas, P. L-arginine in cardiovascular disease: dream or reality? Vasc. Med., 2002, 7(3), 203-211.
199. Tentolouris, C.; Tousoulis, D.; Davies, G. J.; Stefanadis, C.; Toutouzas, P. Serum cholesterol level, cigarette smoking, and vasomotor responses to L-arginine in narrowed epicardial coronary arteries. Am. J. Cardiol., 2000, 85(4), 500-503, A511.
200. Siasos, G.; Tousoulis, D.; Antoniades, C.; Stefanadi, E.; Stefanadis, C. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int. J. Cardiol., 2007, 116(3), 300-308.
201. Walker, N.; Howe, C.; Bullen, C.; Grigg, M.; Glover, M.; McRobbie, H.; Laugesen, M.; Parag, V.; Whittaker, R. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction, 2012, 107(10), 1857-1867.